ChemBK
  • Home
  • Product Category
  • CHN
  1. Home
  2. CAS 1365267-33-9
  3. Supplier List
  4. MedChemExpress (MCE)
  5. Inhibitory Antibodies
  6. Codrituzumab

Request for quotation








Supplier Contact

Supplier NameMedChemExpress (MCE)
Contactsales
Tel609-228-6898
Mobile609-228-6898
QQ
Emailsales@medchemexpress.com; tech@medchemexpress.com
Websitehttps://www.medchemexpress.com/
Wechat
Product NameCodrituzumab
SynonymsCodrituzumab
CAS1365267-33-9
EINECS
Chemical Formula
Molecular Weight
inchi
Package1 mg;5 mg
PriceEmail to quote
DescriptionsCodrituzumab

Codrituzumab

MedChemExpress (MCE)

HY-P99013

1365267-33-9

GC33

Descriptions

Codrituzumab

Codrituzumab

MedChemExpress (MCE)

HY-P99013

1365267-33-9

GC33
RO5137382

95.70%

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping with dry ice.

Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth.

Codrituzumab (once-weekly for 21 days) combined with PD-L1 mAb demonstrates a marked antitumor effect, enhancing tumor infiltration of PD-L1-positive immune cells, such as macrophages and multinucleated giant cells in the Hepa1-6/hGPC3 mice model[1].

Humanized

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

| | | |

| | | | | |



[1]. Mika Endo, et al. Abstract 2747: Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1 monoclonal antibody promotes antitumor effects. Cancer Res (2018) 78 (13_Supplement): 2747.

[2]. Chen G, et al. Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget. 2018 Jan 2
9(12):10436-10444.
[Content Brief]

[3]. Carrasquillo JA, et al. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res. 2018 Mar 5
8(1):20.
[Content Brief]

[4]. Abou-Alfa GK, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016 Aug
65(2):289-95.
[Content Brief]

Supplier Websitehttps://www.medchemexpress.com/codrituzumab.html
Last Update2025-05-21 16:50:25
MedChemExpress (MCE) also provides

Depatuxizumab

Category: Inhibitory Antibodies
CAS: 1471999-69-5
Last Update: 2025-05-21 16:50:25

Raxibacumab

Category: Inhibitory Antibodies
CAS: 565451-13-0
Last Update: 2025-05-21 16:50:25

Crizanlizumab

Category: Inhibitory Antibodies
CAS: 1690318-25-2
Last Update: 2025-05-21 16:50:25

Sofituzumab vedotin

Category: Inhibitory Antibodies
CAS: 1418200-58-4
Last Update: 2025-05-21 16:50:25

Fazpilodemab

Category: Inhibitory Antibodies
CAS: 2517935-02-1
Last Update: 2025-05-21 16:50:25

Osemitamab

Category: Inhibitory Antibodies
CAS: 2460539-61-9
Last Update: 2025-05-21 16:50:25

Visugromab

Category: Inhibitory Antibodies
CAS: 2556646-63-8
Last Update: 2025-05-21 16:50:25

Vobramitamab

Category: Inhibitory Antibodies
CAS: 2490556-50-6
Last Update: 2025-05-21 16:50:25
  • Home
  • Product Category

© 2015 ChemBK.com All Rights Reserved | Build: 20150530002